Bonomarlot
A-20, bone marrow peptide bioregulator
Bonomarlot is a bone-marrow peptide complex sold as capsules. It is the clearest example on this site of a page that used to say nothing, because the half-life field read 'not characterized' and the writing stopped there. The oral route is what makes it worth a page: it is the one compound in this cohort where the pharmacokinetic question is not academic.
Bonomarlot quick facts
| Reported research dose | 40-160mg daily (1-2 capsules, 1-2x daily with food · 40mg/capsule) |
| Route | Oral |
| Frequency | 1-2x Daily · Daily during a course |
| Half-life | Not characterized |
| Forms | Oral |
| Evidence level | Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it |
The Khavinson literature behind this is decades deep, almost entirely Russian-language, and rarely replicated by any independent group — small single-arm series rather than controlled trials. Absence of replication is not evidence it fails; it is an absence of the evidence that would settle it either way. Dose and course length follow the manufacturer's convention, not a trial. Marrow-directed — the bone-marrow bioregulator of the set. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, a CBC — marrow output is one of the few things in this set with a direct cheap readout. Run it as an experiment you measure, not a protocol you trust.
What Bonomarlot actually is — and why that changes the mechanism
Bonomarlot is a bone-marrow peptide complex — an extract, sold orally, with no sequence, no mass and no published identification of any component. It is the emptiest page in this cohort in terms of primary literature, and the most interesting one in terms of what the arithmetic can still establish.
The mechanism claim, and the two things wrong with it. The class story is that short peptides reach the nucleus and modulate transcription in a tissue-specific way. Applied here it fails twice. First, the argument was built for defined two-to- four-residue molecules with computed DNA interactions; this is an unspecified mixture. Second, and more concretely: the delivery mechanism that makes an oral short peptide arguable at all is PEPT1, the proton- coupled transporter on the brush-border membrane of the small intestine, whose substrate range the originating group's own review describes as “basically all di- and tripeptides”. A peptide complex of unknown chain length is not a di- or tripeptide. The one named route by which this product could work is a route it does not qualify for.
What that leaves. An oral tissue extract whose claimed mechanism requires a transporter that does not carry it. That is a specific, checkable objection rather than general scepticism, and it is the honest center of this page.
What the primary literature on Bonomarlot actually says
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
The load-bearing citation for any oral bioregulator. PEPT1 and PEPT2 'have a broad substrate pattern that includes basically all di- and tripeptides', and PEPT1 sits on the brush-border membrane of the small intestine. That is a real, well-characterized route by which an intact small peptide can cross the gut wall — and it is a route for di- and tripeptides, not for a protein hydrolysate.
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
The class evidence base, cited for what it covers: thymus and pineal extracts, injected, in 266 elderly subjects. Not this tissue and not this route.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Independent calibration on how this class fares when someone outside it grades the evidence.
What is not here. Nothing is indexed under the trade name Bonomarlot. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Bonomarlot evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Bonomarlot. Nothing is indexed under this trade name — no trial, no animal study, no mechanism paper. The bone-marrow claim is a tissue-specificity assertion with no published readout in any species. On top of that sits a route problem: the transporter argument that makes oral short peptides plausible applies to di- and tripeptides, and this product is a complex. The honest position is that neither the claim nor the delivery has been demonstrated.
What the data does support: nothing, under this name. Nothing is indexed for Bonomarlot — no trial, no animal study, no mechanism paper, in any language this search could reach. The bone-marrow claim is a tissue-specificity assertion with no published readout in any species.
The nearby citations are cited for what they are not. The 266-subject elderly series studied thymus and pineal extracts, injected — not this tissue and not this route. The independent systematic review that graded this drug class looked at cognitive disorders and found risk of bias moderate to high with certainty of evidence low to very low — calibration on the class, not evidence about marrow.
The specific epistemic position, and it is the starkest in the cohort: this is not a compound whose trial failed, because there is no trial. It is not a compound whose mechanism was refuted, because no mechanism study exists for it. Every word written about it anywhere is inference from a class. That is an absence of evidence rather than evidence of absence — and an absence this complete is itself the most important finding on the page.
What is actually measured, and what is not. This marrow preparation has no trial, no animal study, no effect size and no mechanism paper under its own name. Not one cell-culture experiment on it has been published. Its pharmacokinetics have never been investigated in any species. The half-life of whatever it contains is unrecorded. Nobody has described its clearance. Its composition has never been resolved, so no molecule can be tested against the nuclear-entry claim. Nobody has shown a component surviving brush-border peptidase activity. Nobody has quantified the fraction crossing the gut wall, and the oral route stands or falls on that single number. Transcription in marrow has never been measured under it. Marrow output also runs to a known clock, which makes the absence conspicuous: a reticulocyte response takes 1–2 weeks and a hemoglobin change takes 8–12 weeks. No experiment lasting that long has ever been run on this product. No lymphocyte, platelet or red-cell count has been reported from any experiment at all. The 2003 elderly series that anchors the class gave thymus and pineal extracts by injection over 6–8 years, which is neither this tissue nor this route.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Bonomarlot pharmacokinetics — how much of it actually gets in
“Not characterized” is accurate. Here is what it should say next. A half-life describes one compound's clearance; a mixture has as many curves as it has components, so no single figure could be right. Nothing has been measured for this preparation in any species.
What can be reasoned. Peptide components meet serum aminopeptidases and clear in minutes — which does not sink the mechanism, because a transcriptional signal outlasts the molecule, but does mean the interesting number is absorption rather than clearance.
Now do the arithmetic the blank was hiding. Compare the oral products in this class against the injectable ones and the oral form carries roughly 29x more material per day, and on the order of 571x more across a full course. Take an injection as fully bioavailable — 100% by definition, no gut wall, no hepatic first-pass — and the implication is direct: for the oral route to deliver comparable systemic exposure, on the order of 0.2% of what is swallowed would have to arrive in the circulation intact. Whether a peptide mixture can manage that has never been measured — not for this product and not for any product in this family. Stating the bound is honest. Claiming the fraction would not be.
What would have to be true for Bonomarlot to work
What would have to be true. The complex would have to contain active peptides — unpublished; enough of them would have to survive the stomach and cross the gut wall — through a transporter that does not carry them; reach marrow; and change hematopoiesis measurably. Step two is the one this product cannot currently argue for at all, and it comes before everything else.
Marrow is unusually good to test on, because erythropoiesis runs to a known clock and the predictions can be ordered — which makes a coincidence much harder to mistake for an effect.
- Prediction 1 — Complete Blood Count (CBC) with Differential. hemoglobin, MCV and the differential should move if a marrow claim means anything, 8–12 weeks — one full red-cell turnover. A marrow effect cannot show up faster than erythropoiesis allows. Anyone reporting a change in two weeks is reporting something else.
- Prediction 2 — Reticulocyte count. should rise first, before hemoglobin does, 1–2 weeks. This is the specific, ordered prediction that would separate a real marrow effect from a coincidence: reticulocytes lead hemoglobin. If hemoglobin rises without a preceding reticulocyte response, the marrow is not what changed.
- Prediction 3 — ferritin. should be checked first, because it is the likelier answer, before starting. Most low counts in this population have a cause that is cheaper to fix than this is to buy.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Bonomarlot did to it — and that difference is the entire point of testing.
Bonomarlot versus the alternatives
Bonomarlot versus Vilon. Vilon is Lys-Glu, the defined dipeptide with the highest computed DNA affinity in its class and a mouse lifespan study; Bonomarlot is a marrow extract with no indexed literature. On verifiability the peptide wins outright — it has a mass a laboratory can confirm. On clinical evidence neither has anything, and the extract's additional problem is that its stated oral route has no delivery mechanism behind it.
And against the credible alternative, which is the important paragraph on this page. Low blood counts have causes, and the causes are diagnosable: iron deficiency, B12 or folate deficiency, thyroid disease, chronic inflammation, blood loss, marrow pathology. Every one of those has a test and a treatment with real evidence, and several of them are cheap. Taking an unstudied oral extract for a low count risks treating a number instead of finding out why it is low. That comparison does not go well for this product and avoiding it is exactly why this category is not trusted.
What you are actually buying when you buy Bonomarlot
Bonomarlot is an extract, not a molecule. A certificate of analysis can establish sterility, endotoxin, total protein and the absence of named contaminants. It cannot establish identity, because there is no structure to identify — the product is defined by its process. Two vials with clean certificates can hold different mixtures.
An oral capsule adds a second question a certificate never answers. A CoA describes what is in the capsule. It says nothing about what leaves the gut — and for this product, where the claimed mechanism requires a transporter its contents do not fit, that is the question that decides whether anything happens at all. No vendor certificate in this market addresses it, because none can.
An oral capsule adds a question an injectable does not have: what fraction survives the stomach and the brush border. Nobody has published that number for this product, and no certificate of analysis addresses it — a CoA describes what is in the capsule, not what gets out of the gut.
Where to get Bonomarlot
Buy Bonomarlot at BioLongevity Supplements →The evidence for Bonomarlot
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
🧪 How the mechanism reads
- The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern. It is a coherent mechanism and it is why these are dosed as short courses rather than continuously.
- Oral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut, which is why the oral capsules run 10-20x the injectable milligram dose. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
What that tier rests on here. The tier above is class inference and nothing else. Nothing whatever is indexed under the trade name Bonomarlot — no trial, no animal study, no mechanism paper — and the oral route it is sold in has no named transport mechanism behind it.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
The nearest thing to a bone-marrow result in this school is a COVID-19 treatment paper. Khavinson 2021 appears in Stem Cell Reviews and Reports and describes a thymus peptide drug used in patients with COVID-19, with the group proposing that part of its mechanism is an effect on the differentiation of human hematopoietic stem cells. The reported outcomes are inflammatory: faster falls in IL-6, C-reactive protein and D-dimer than standard therapy alone. No marrow was examined and no blood count was the endpoint.
An independent group works on adjacent chemistry. Deigin 2022 describes the tripeptide Ile-Glu-Trp as an adjuvant producing a balanced immune response. Different laboratory, different molecule, no marrow endpoint either — but it is a second set of hands in the same neighborhood, which is more than most pages in this cohort can say.
Marrow is absent from the group's own extract survey. Ryzhak 2015 tested cortex, pineal, liver, prostate, thymus, heart and cartilage in organotypic culture. Bone marrow is not among the seven, so this tissue has no explant result behind it either. A PubTator3 search under the trade name on 6 September 2026 returned nothing.
Where it stops, and why this one is the sharpest omission in the cohort. A complete blood count is the most frequently ordered test in medicine. It measures, directly and cheaply, the output of the organ this product is named for: hemoglobin, red cell count, white cell count with differential, platelets, and reticulocytes for marrow activity specifically. Not one published study of this class has ever reported one.
What nobody has tested yet
A CBC with reticulocyte count, before and eight weeks after. Reticulocytes are newly released red cells, they respond within days to a change in marrow output, and they are the single most direct read-out of the claim on this label. The test is available anywhere blood is drawn and costs very little. That it has never been reported for a bone-marrow product is the clearest statement this page can make about the state of the evidence.
Ferritin, B12 and folate belong in the same draw. They are the substrate side of hematopoiesis, they are the common and correctable causes of the symptoms this product is bought for, and correcting a deficiency will move a blood count far harder than any unstudied capsule. Measuring them first is also what makes any before-and-after pair interpretable.
Extrapolation, labeled as such. If a marrow preparation genuinely nudged stem cell differentiation, the effect should be visible as a lineage shift — a change in the ratio between red, white and platelet output — rather than as a uniform rise. A differential count would show that pattern and nothing else would. It is a specific, cheap and falsifiable prediction, and it has never been looked for in any species.
Sources read for this page
- Khavinson VK. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Reviews and Reports 2021 · PMID 33575961
- Deigin V. Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. International Journal of Peptide Research and Therapeutics 2022 · PMID 36313476
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Bonomarlot — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Bonomarlot — safety specifics for this compound
Specific to Bonomarlot: an oral animal-tissue extract has a different risk profile from an injectable one — lower infection risk, but no sterility guarantee once swallowed matters less than what the preparation contains, and the contents are unpublished. The named clinical risk here is not toxicity: it is that a low blood count is a diagnostic finding, and using an unstudied product to nudge it can delay identifying a cause that matters. The marker at issue is a CBC with differential: a hemoglobin or platelet count that will not come up has causes worth finding, and iron studies, B12 and a reticulocyte count are the tests that find them. Nothing in the literature reports harm from this compound, and nothing reports anything about it — 0 trials, in the 24-trial independent review of this class and everywhere else.
Bonomarlot — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Bonomarlot moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Bonomarlot in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Bonomarlot
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Bonomarlot — frequently asked questions
Is Bonomarlot a peptide or an extract?
An extract — a peptide complex from bone marrow, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Bonomarlot?
Nothing is indexed under the trade name Bonomarlot.
What should I measure if I run Bonomarlot?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
What Bonomarlot is used for
Bonomarlot appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.